Needham analyst David Saxon reiterated a Buy rating on CryoPort (NASDAQ:CYRX) Inc on Thursday, setting a price target of $79, which is approximately 41.93% above the present share price of $55.66.
Saxon expects CryoPort Inc to post earnings per share (EPS) of -$0.16 for the third quarter of 2021.
The current consensus among 4 TipRanks analysts is for a Strong Buy rating of shares in CryoPort, with an average price target of $79.
The analysts price targets range from a high of $80 to a low of $78.
In its latest earnings report, released on 06/30/2021, the company reported a quarterly revenue of $56.19 million and a net profit of -$3.75 million. The company's market cap is $2.56 billion.
According to TipRanks.com, Needham analyst David Saxon is currently ranked with 2 stars on a 0-5 stars ranking scale, with an average return of 5.1% and a 33.33% success rate.
CryoPort, Inc. engages in the provision of logistics solutions to the life science industry. It also provides logistics solutions for biologic materials such as immunotherapies, stem cells, CAR-T cells, and reproductive cells for clients worldwide, including points-of-care, clinical research organizations central laboratories, biopharmaceuticals, contract manufacturing, health centers, and university researchers. It offers personalized medicine, immunotherapies, cellular therapies, CAR T-cell therapies, stem cell therapies, cell lines, vaccines, diagnostic materials, semen, eggs, embryos, cord blood, bio-pharmaceuticals, infectious substances, and other commodities that require continuous exposure to certain ranges of precision-controlled temperatures. The company was founded on May 25, 1990 and is headquartered in Irvine, CA.